|
AstraZeneca PLC on Thursday priced a global bond offering worth $2 billion. Shares in the Cambridge, England-based pharmaceutical firm rose 0.7% to 15,320.00 pence on Thursday morning in London. AstraZeneca has registered the offering, which is being carried out in three tranches by wholly-owned subsidiary AstraZeneca Finance LLC, with the US Securities & Exchange Commission. The first tranche will comprise $650 million of fixed rate notes with a coupon of 4.0%, maturing March 2, 2031. The second tranche is for $600 million, with notes carrying a 4.3% coupon and maturing on the same date in 2033. The final tranche is worth $750 million, where notes will have a 4.6% coupon and mature on the same date in 2036. ‘AstraZeneca expects to use the net proceeds of the offering for general corporate purposes, which may include the refinancing of existing indebtedness,’ the firm said. It added that the bond issuance does not affect its 2026 financial outlook. Bank of America Securities Inc, Deutsche Bank Securities Inc, HSBC Securities USA Inc and Mizuho Securities USA LLC are acting as joint bookrunners for the transaction. Copyright 2026 Alliance News Ltd. All Rights Reserved.
|
